Myelofibrosis
Not recruitingStudy of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment
Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment
- Disease:Myelofibrosis
- Substances:Imetelstat SodiumOther sex hormones and modulators of the genital system
Spain- Participants:18–64 years · 65+ years
- Substances:Imetelstat Sodium
- Sponsor:Geron Corp.









